SPY падает на премаркете

Ближайший уровень поддержки по SPY – 196.75 уровень сопротивления – 197.25



AGIO продажа ниже 64

NKE продажа от 89

LLL продажа от 114.75

IRM покупка выше 32

Gapping up/down: AMBI +88%, DWA +26%, ATHL +24%, TIBX +21% and AMAG +15% on M&A related news; HIMX +2% on upgrade; EU financials, select energy and metal names trading lower; AVY -1% on dg at JPM Price: null Change: null 

Gapping up 
In reaction to strong earnings/guidance: RCON +7.2%, LAS +2.3%, KOOL +1.7%, CALM +1.2%, ADP +0.7%

M&A news: AMBI +87.8% (Daiichi Sankyo (DSNKY) to acquire Ambit Biosciences for $15 per share in cash through a tender offer), DWA +26.4% (Softbank (SFTBY) is in discussions to purchase DWA, according to reports, Variety discusses comments from sources that chances of Softbank (SFTBY) acquiring DWA are slim), ATHL +24.6% (Encana (ECA) to acquire all of the issued and outstanding shares of common stock of Athlon by means of an all-cash tender offer for $58.50 per share), TIBX +21% (to be acquired by Vista Equity Partners for $24.00 per share in cash), AMAG +15.4% (to acquire Lumara Health for $600 mln in cash and $75 mln in stock and additional contingent consideration of up to $350 mln)

Other news: EXEL +18.6% (announces positive results from Phase 3 pivotal trial of Cobimetinib in combination with Vemurafenib in patients with BRAF V600 Mutation-positive advanced melanoma), ALIM +16.6% (provides details on FDA approval Of ILUVIEN as the first long-term treatment for diabetic macular edema), ECYT +10.2% (Phase 2b TARGET trial results show improved survival in Adenocarcinoma non-small cell lung cancer patients treated with Endocyte's Vintafolide), PSDV +9.8% (reports approval of ILUVIEN for diabetic macular edema; triggers $25 mln milestone payment from Alimera Sciences (ALIM)), CYTR +7.9% (receives multiple FDA Orphan Drug designations for Aldoxorubicin for the treatment of Glioblastoma), PE +5.6% (still checking), ACST +4.1% (reports successful CaPre Phase II TRIFECTA results proving statistically significant improvements in triglycerides & non-HDL-C), ARIA +4% (announces updated clinical results for AP26113, study results show sustained anti-tumor activity), SGEN +3.9% (Seattle Genetics and Takeda (TKPYY) announce positive data from Phase 3 AETHERA clinical trial of ADCETRIS), KMDA +3.3% (announces second extension of Strategic Agreement with Baxter (BAX)), ISR +3.1% (still checking), DATE +3% (declared a special one-time cash dividend of $0.4467 per ordinary share, or $0.67 per American Depositary Share), WEX +1.4% (positive commentary on Friday's Mad Money)


Analyst comments: HIMX +2.2% (upgraded to Buy from Hold at Craig Hallum), SAH +1.4% (upgraded to Overweight from Underweight at Morgan Stanley), BIDU +0.7% (upgraded to Buy from Neutral at UBS)

Gapping down
In reaction to disappointing earnings/guidance: ELGX -2%, FGP -1.4%

Select EU financial related names showing weakness: HSBC -2.1%, NBG -2%, BCS -1.5%, LYG -1.4%, ING -1.3%, DB -1.1%

Select metals/mining stocks trading lower: VALE -3.6%, CLF -2.4%, X -2.1%, RIO -1.8%, BHP -1.5%

Select oil/gas related names showing early weakness: PBR -3.9%, CEO -2.2%, TOT -1%, BP -0.5%.

Other news: NXTD -8.3% (reports Wocket is in production), JNS -1.7% (slight pull back following Friday's 40%+ move higher), OLBK -1.6% (announces plans for branch consolidation), BBRY -1.3% (still checking), TSLA -1.3% (WSJ discusses that many in China are still skeptical regarding TSLA China stations), AAPL -1.2% (several stories out over weekend, may be attributed to news that AAPL may be accused of illegal Irish tax deals)

Analyst comments: EMKR -3.2% (downgraded to Hold from Buy at Needham), AVY -1.2% (downgraded to Neutral from Overweight at JP Morgan), DE -0.5% (target lowered to $95 from $98 at Credit Suisse), DRC -0.5% (downgraded to Neutral from Buy at Guggenheim)

Оригинал статьи: gtstocks.com/analytics-29-09-2014.html